Thus, we demonstrated that FABP4 and MMP9 hepatic mRNA expression levels could be used as predictive markers for clinical outcomes in patients with NAFL and/or NASH and we were able to build a prediction model (Fig. 6D). This evidence concerns the gene FABP4 and metabolic dysfunction-associated steatohepatitis.